1.Bristol Myers Squibb - Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung … (bms.com)
2.Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation | New England Journal of Medicine (nejm.org)
3.cd-24-0217.pdf (silverchair.com)
4.Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer | Cancer Research | American Association for Cancer Research (aacrjournals.org)